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Feline immunodeficiency virus (FIV) is a 
lentivirus that can infect several feline spe-
cies, among them the domestic cat. Related 
lentiviruses are prevalent in non-domestic 
felids (Olmsted et al., 1992). The isola-
tion of FIV from cats who while having an 
immunodeficiency-like illness were seron-
egative for Feline leukemia virus (FeLV), 
was first described in 1987 (Pedersen et al., 
1987). FIV is classified into five phyloge-
netic subtypes, A through E, according to 
the nucleotide sequence diversity in the 
env gene that encodes for the viral envelop 
proteins. Subtypes A and B are most preva-
lent worldwide (Samman et al., 2011). The 
seroprevalence differs between regions, with 
1–14% in clinically asymptomatic domes-
tic cats and up to 44% in sick cats (Hosie 
et al., 2009).
Feline immunodeficiency virus transmis-
sion occurs naturally mainly through biting, 
but vertical transmission between mother 
and kittens is also possible (Yamamoto 
et al., 1989). Transmission occurs more 
easily when an uninfected cat is exposed to 
infected cells, although lower levels of the 
virus are also present in colostrum, saliva, 
plasma, and seminal fluid (Yamamoto et al., 
2007). After acute infection FIV can cause a 
AIDS-like syndrome in domestic cats, with 
many similarities to HIV-induced AIDS in 
man (Elder et al., 2010). Progression of the 
chronic lentivirus infection is associated 
with a decline in CD4+ T lymphocytes and 
CD4+:CD8+ ratio during a asymptomatic 
phase. During this period plasma virus 
load remains stable (Hosie et al., 2009). 
When the CD4+ T lymphocyte count falls 
below a certain number immune dysfunc-
tion will become apparent, accompanied 
by secondary and opportunistic infec-
tions (Willett et al., 1997). In addition to 
the ability to infect CD4+ T lymphocytes, 
FIV also infects several other immune cells, 
including monocytes/macrophages, B cells, 
CD4+CD25+ T cells, and CD8+ T cells 
(Yamamoto et al., 2007).
(Figure 1). This hyper-activation is seen in 
both CD4+ and CD8+ T lymphocyte popula-
tions, with a rise in B7+CTLA4+ phenotype, 
and increase in B lymphocyte polyclonal 
responses (Tompkins and Tompkins, 2008). 
The B7+CTLA4+ T lymphocytes cause an 
induction of anergy and apoptosis through 
T–T lymphocyte interactions, which leads 
to CD4+ T lymphocyte depletion.
Partly the depletion of CD4+ T lym-
phocytes may also be due to the activation 
of CD4+CD25+ T regulatory (Treg) cells 
in FIV-infected cats. Previous studies sug-
gested that a proper immune response is lost 
during the acute phase FIV infection (Mexas 
et al., 2008). It’s possible that CD4+CD25+ 
T regulatory lymphocytes induce anergy in 
CD4+ and CD8+ T cells (Vahlenkamp et al., 
2004). This knowing, it could be meaningful 
investigating which mechanisms cause the 
activation of CD4+CD25+ Treg cells and if 
it can be suppressed effectively during the 
acute phase of FIV infections, without los-
ing an effective immune response. CD4+ 
and CD8+ T-cells functioning may improve 
when CD4+CD25+ Treg cells are suppressed 
and slow progression to AIDS.
Currently practiced therapy focuses 
on immune stimulation, vaccination, and 
treatment of secondary diseases. Immune 
stimulation has been suggested in the form 
of GM-CSF, IFN-alpha, and IFN-tau among 
others (Arai et al., 2000; Pedretti et al., 2006; 
Chon and Bixler, 2010). These therapies 
are based on the notion that the CD4+ T 
lymphocyte depletion in feline AIDS is the 
direct consequence of viral killing by FIV 
(the “viral killing hypothesis”). In this theory 
high turnover of T lymphocytes and eventu-
ally exhaustion is a response to viral destruc-
tion of CD4+ T lymphocytes. It has also been 
suggested however, that activation-induced 
CD4+ T lymphocyte death may be a major 
factor in progression to AIDS in humans 
(Groux et al., 1992; Hazenberg et al., 2003), 
which corresponds with the absence of 
CD4+ T lymphocyte decline in naturally 
Simian immunodeficiency virus (SIV) 
infected Sooty Mangabeys (Silvestri et al., 
2003). These primates show a high viral 
load, but limited SIV CD4+ T lymphocyte 
cytopathicity. Therefore chronic (hyper-)
activation of the immune system may also 
play a significant role in FIV pathogenesis 
Figure 1 | Chronic antigenemia induces immune hyper-activation that leads to immune 
suppression. This process may be inhibited by anti-inflammatory or immunosuppressive drugs that reduce 
T-cell activation.
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In light of this evidence it is important 
to explore the effectiveness of immunosup-
pressive or anti-inflammatory treatment in 
the prevention of progression to AIDS in 
FIV-infected cats. Suggested pharmaceuti-
cals for this type of treatment for HIV are 
cyclosporin A and corticosteroids (Groux 
et al., 1992; Lawn et al., 2001). It should 
however be noted that although this type 
of treatment may diminish the detrimental 
effect of immune hyper-activation, antiret-
roviral drugs, that for example inhibit FIV 
enzymes (Savarino et al., 2007), should be 
used or developed to alleviate the poten-
tial effects of immunosuppression on viral 
replication.
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